US 2014/0030244 A1Published application

Extracts isolated from electroporated ambhibian oocytes and use thereof in treating diseases and disorders

AssigneeBioquark, Inc.

InventorSergei Paylian

Life of this patent

Estimating the term…

Loading patent…

Abstract

The described invention provides methods for preparing a composition containing extracts of activated amphibian oocytes, the method where the composition is a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and a method for treating a disease, disorder, condition or injury characterized by a damaged or a cancerous differentiated cell including: (a) preparing the composition by the described method; (b) formulating a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and optionally a carrier; and (c) administering a therapeutic amount of the pharmaceutical composition of (b) to a subject in need thereof, where the therapeutic amount is effective to reprogram the damaged or cancerous cells into iPSC-like cells capable of differentiating into cells capable of repairing the damaged or cancerous cells, thereby treating the disease, disorder, injury or condition.

Claims57

Dependent claims

A method for preparing a composition comprising extracts of activated amphibian oocytes comprising:

(a) providing a suspension of oocytes harvested from an amphibian, in a buffered oocyte washing solution in an oocyte activation vessel;
(b) applying an electroporation stimulus to the suspended oocytes of (a) in the oocyte activation vessel to produce a suspension of activated oocytes;
(c) combining an aqueous energy solution with the suspension of activated oocytes to form an aqueous suspension;
(d) incubating the aqueous suspension of (c) at an incubation temperature of 16° C. to 20° C., for an incubation time of about 2 to about 4 hours;
(e) partitioning the incubated combination of (d) to obtain a portion external to the incubated activated oocytes (extra-oocyte portion), and an activated oocyte portion that includes the incubated activated oocytes of (d);
(f) separating the extra-oocyte portion and the activated oocyte portion from each other;
(g) filtering the extra-oocyte portion to produce an extra-oocyte composition;
(h) rupturing the activated oocyte portion of (f) comprising a light fraction, a heavy fraction and a cytoplasmic fraction;
(i) separating the cytoplasmic fraction from the light fraction and the heavy fraction to produce a combination of the light fraction and the heavy fraction;
and
(j) filtering the combination of (i) to obtain an intra-oocyte composition.

8 more elements

A method for treating a disease, disorder, condition or injury characterized by a damaged or cancerous differentiated cell comprising:

(a) preparing a composition by:
(1) providing a suspension of oocytes harvested from an amphibian, in a buffered oocyte washing solution in an oocyte activation vessel;
(2) applying an electroporation stimulus to the suspended oocytes of (1) in the oocyte activation vessel to produce a suspension of activated oocytes;
(3) combining an aqueous energy solution with the suspension of activated oocytes to form an aqueous suspension;
(4) incubating the aqueous suspension of (3) at an incubation temperature of 16° C. to 20° C., for an incubation time of about 2 to about 4 hours;
(5) partitioning the incubated combination of (4) to obtain a portion external to the incubated activated oocytes (extra-oocyte portion), and an activated oocyte portion that includes the incubated activated oocytes of (4);
(6) separating the extra-oocyte portion and the activated oocyte portion from each other;
(7) filtering the extra-oocyte portion to produce an extra-oocyte composition;
(8) rupturing the activated oocyte portion of (6) to produce a light fraction, a heavy fraction and a cytoplasmic fraction;
(9) separating the cytoplasmic fraction from the light fraction and the heavy fraction to produce a combination of the light fraction and the heavy fraction;
and
(10) filtering the combination of (9) to obtain an intra-oocyte composition;
(b) formulating a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and optionally a carrier;
and
(c) administering a therapeutic amount of the pharmaceutical composition of (b) to a subject in need thereof,
wherein the therapeutic amount is effective to reprogram the damaged or cancerous cells into iPSC-like cells capable of differentiating into cells capable of repairing the damaged or cancerous cells, thereby treating the disease, disorder, injury or condition.

13 more elements

Dependencies are inferred from the claim text.

Facts

Application: 13/949,977Filed 24 Jul 2013
Priority: 27 Jul 2012
Published: 30 Jan 2014
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 35/65
Materials from animals other than mammals: amphibians, e.g. toads, frogs, salamanders or newts
A61K 31/7105
Compounds having three or more nucleosides or nucleotides: natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine,…
A61K 38/1703
From animals; from humans: from vertebrates
A61K 38/45
Enzymes; Proenzymes; Derivatives thereof: transferases